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Abstract
Takotsubo cardiomyopathy, also known as broken heart syndrome or stress 
cardiomyopathy, is a form of transient left ventricular dysfunction. Severe apical 
and mid left ventricular hypokinesis with hypercontractility of the basal segments 
is observed. Numerous underlying causes and pathophysiological mechanisms have 
been proposed including sudden sympathetic activation and increase in the circu-
lating levels of catecholamines resulting in multivessel coronary spasm. Another 
possible mechanism related to catecholamine-mediated myocardial stunning is 
direct myocyte injury. Increasing data show that endothelial dysfunction and 
depleted nitric oxide bioavailability are common in patients with Takotsubo car-
diomyopathy. In this chapter we examine in depth the relation between endothelial 
dysfunction and Takotsubo syndrome.
Keywords: Takotsubo cardiomyopathy, broken heart syndrome, nitric oxide, 
endothelial dysfunction, ADMA
1. Introduction
Takotsubo cardiomyopathy (TC), also known as broken heart syndrome or 
stress cardiomyopathy, is a form of transient left ventricular (LV) dysfunction. 
Severe apical and mid left ventricular hypokinesis with hypercontractility of the 
basal segments is observed [1–4]. The name derives from the fact that the shape of 
the LV of patients with Takotsubo syndrome resembles the octopus fishing pot used 
in Japan where the first studied case of TC was done by Sato et al. in the early 1990s 
(Figure 1(a) and (b)).
The InterTAK diagnostic score is a score that predicts the probability of 
Takotsubo cardiomyopathy and differentiates form acute coronary syndrome. 
Female sex and emotional stress yield the highest score. Other predisposing factors 
include physical stress, psychiatric disorders, and neurological disorders.
Takotsubo cardiomyopathy usually presents with shortness of breath, 
hypotension, angina or syncope. Laboratory work may reveal elevated troponin 
levels. Electrocardiogram may show signs of ischemia, such as T wave inversion 
or even ST elevation [1]. Coronary angiogram typically reveals normal coronary 
arteries.
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2. Pathophysiology
The pathophysiology of TC is quite complex and a number of different mecha-
nisms have been proposed, including sudden sympathetic activation and increase 
in the circulating levels of catecholamines resulting in multivessel coronary spasm 
[5–15]. Coronary vasospasm and sympathetic mediated microvascular dysfunction 
have been observed in patients with TC.
According to Gupta et al. [16], the pathophysiology of sympathetic mediated 
coronary vasospasm and microvascular dysfunction can be divided in two phases.
According to the authors, the first phase starts with cognitive centers of the 
brain. As a response to stress, the hypothalamic-pituitary-adrenal axis is activated 
and releases catecholamines. In the case of TC, catecholamine and brain natriuretic 
peptide (BNP) levels are elevated significantly more than in patients with decom-
pensated heart failure after an acute coronary syndrome. Catecholamine levels then 
start to decline, but remain significantly higher than in patients with acute coronary 
syndromes even a week after the event. On the other hand, plasma BNP levels 
decline rapidly, compared to patients with acute coronary events, and this is in paral-
lel with the rapid improvement of the LV systolic function in TC. During the second 
phase, myocardial stunning occurs as a result of increased catecholamine levels.
3. Proposed mechanisms of Takotsubo syndrome
Plasma catecholamine levels are shown to be closely correlated with TC. In 
a study by Wittstein et al. [8], plasma catecholamine levels in 13 patients with 
stress-related myocardial dysfunction were compared with those in 7 patients who 
presented with acute pulmonary edema after myocardial infarction (Killip class III). 
The study showed that plasma catecholamine levels (epinephrine, norepinephrine, 
and dopamine) at presentation were markedly higher among patients with stress-
induced cardiomyopathy than among those with Killip class III myocardial infarc-
tion. According to the results of this study, patients with stress cardiomyopathy had 
Figure 1. 
(a) Angiogram of a patient with Takotsubo cardiomyopathy showing the apical balloning of the left 
ventricle. (b) The Takotsubo fishing pot after syndrome was named. You can appreciate the resemblance with 
angiographic image on the left.
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supraphysiologic levels of plasma catecholamines. Initial plasma levels were several 
times those of patients with myocardial infarction and remained markedly elevated 
even a week after the onset of symptoms [8].
The mechanism underlying the association between sympathetic activity and 
myocardial stunning is unknown.
Increased catecholamine levels result in either direct cardiomyocyte damage 
through increased calcium levels or in vascular spasm and microvascular dys-
function, which leads to ischemia [5–7]. Abnormal coronary flow in the absence 
of obstructive disease has recently been reported in patients with stress-related 
myocardial dysfunction [17]. Increased sympathetic activity and vascular spam also 
cause an increase in left ventricular afterload adding even more to the pathophysiol-
ogy of TC [8].
Oxygen-derived free radical circulating levels can be increased by catechol-
amines and they can cause myocardial injury, which can be attenuated by antioxi-
dants [18]; they can also interfere with sodium and calcium channels, increasing 
trans-sarcolemmal calcium influx resulting in myocyte dysfunction [19].
Oxidative stress often exaggerates myocardial stunning by affecting calcium 
homeostasis and causing excitation-contractive uncoupling resulting in myocardial 
dysfunction [6–8]. The histopathology of the myocardium in this condition differs 
from that found in ischemic insults and includes a neutrophil-predominant inflam-
mation, contraction band necrosis, and fibrosis [9]. These changes probably reflect 
calcium cardiotoxicity rather than ischemic necrosis. The pattern of ventricular wall 
abnormality in TC also points toward a neurally mediated mechanism of cardiac 
injury [11–13].
One other possibility is ischemia resulting from epicardial coronary arterial 
spasm. Increased sympathetic tone from mental stress can cause vasoconstriction in 
patients without coronary disease [20].
A third possible mechanism of catecholamine-mediated myocardial stunning 
is direct myocyte injury. Elevated catecholamine levels decrease the viability of 
myocytes through cyclic AMP-mediated calcium overload [21].
4. Nitric oxide: endothelial dysfunction and Takotsubo cardiomyopathy
In 1980, Furchgott and Zawadzki [22] identified the “endothelium-derived 
relaxing factor” (later recognized as the free gas nitric oxide (NO)) as responsible 
for the relaxation of vascular smooth muscle cells in response to acetylcholine.
NO is synthesized by the enzyme NO synthase (NOS). This enzyme was 
first identified and described in the late 1980s. The enzyme NOS catalyzes the 
biosynthesis of NO through a reaction involving the conversion of L-arginine to 
L-citruline [23]. NOS is a dimer consisting of two identical monomers, which can 
be divided into two major domains: the C-terminal reductase and the N-terminal 
oxygenase domain [24]. It contains binding sites for flavin adenine nucleotide 
(FAD), nicotinamide adenine dinucleotide phosphate (NADPH) and flavin mono-
nucleotide (FMN) in close relation with cytochrome P-450 reductase. The latter 
binds haem, tetrahydrobiopterin (BH4), and L-arginine, which acts as a substrate.
There are three different NOS isoforms, which differ between them in struc-
ture and function [25]. Endothelial NOS (eNOS) and neuronal NOS (nNOS) are 
Ca2+-dependent enzymes (despite the fact that eNOS can be activated and in an 
Ca2+-independent manner) [26]. Inducible NOS (iNOS) is only expressed at high 
levels after induction by cytokines (thus the name inducible) or other inflam-
matory agents. Its activity is independent of intracellular Ca2+ levels. The three 
NOS isoforms are similar in the way that they have regions of high homology 
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(the oxygenase and the reductase domains) while at the same time each isoform 
exhibits unique features, which signify their specific functions.
The main source of endothelial NO production is eNOS. Specific properties 
of eNOS enable the enzyme to perform its specialized functions. These are Ca2+ 
sensitivity and the post-translational modifications, which facilitate sub-cellular 
localization. These properties enable eNOS to respond not only to hemodynamic 
forces but to neurohormonal agents as well. There are several factors such as estro-
gens, hypoxia, and exercise that are known to modify its expression, likely having 
an impact on cardiovascular function.
4.1 Physiological role of NO: role of NO in vasomotion (vasorelaxation)
As mentioned above, Furchgott and Zawadzki [22] first demonstrated that 
endothelium reversed the intrinsic constrictive effects of acetylcholine on the 
vascular smooth muscle through the release of NO. Numerous experimental and 
clinical studies confirmed that all the arterial endothelium, and to a lesser extent 
vein endothelium, releases NO. When the endothelium is normal, vasoconstriction 
is counteracted by the potent vasorelaxing effect of NO. The importance of NO in 
vasodilation varies between vascular beds and among animal species. Chemical 
modifications of the guanidino group of L-arginine result in compounds that 
inhibit NO synthase. NG-nitro-L-arginine (L-NA), NG-monomethyl-L-arginine 
(L-NMMA), and NG-nitro-L-arginine methyl ester (L-NAME) inhibit the release 
of NO from endothelial cells, indicating that there is continuous release of NO, 
which maintains the vasodilator tone.
4.2 The role of L-arginine analogues in eNOS function
ADMA is an amino acid that circulates in plasma, is excreted in urine, and is 
found in tissues and cells [27–29]. ADMA synthesis involves methylation of arginine 
residues by protein arginine methyltransferases (PRMTs) [30]. During methyla-
tion, either one or two methyl groups are added to the guanidine nitrogens of argi-
nine, which are incorporated into proteins. There are two types of PRMT. Type 1 
catalyzes the formation of ADMA and type 2 catalyzes the formation of symmetric 
dimethylarginine (SDMA) through the methylation of both guanidino nitrogens. 
Both PRMTs can monomethylate as well. Monomethylation leads to the formation 
of another asymmetrical form called NG-monomethyl-L-arginine (L-NMMA) [31].
The asymmetrical forms (ADMA and L-NMMA) are natural inhibitors of all 
NOS isoforms, whereas the symmetrical form (SDMA) is not. ADMA and L-NMMA 
inhibit all three isoforms of NOS [32, 33]. L-NMMA may also uncouple NOS leading 
to the generation of free radicals and more specific of superoxide [34]. Superoxide 
formation by this process further results in myocardial injury seen in TC.
Increased sympathetic activity and alterations in NO synthesis attributable to 
accumulation of ADMA is now recognized as an important mechanism involved in 
cardiovascular complications [35].
ADMA plasma levels are found to be related to insulin resistance, blood pres-
sure, carotid intima thickness, and age even in healthy individuals, free from 
cardiovascular disease [36, 37] suggesting that increased ADMA levels are a marker 
for arteriosclerotic changes.
4.3 Endothelial dysfunction and TC
Increasing data show that endothelial dysfunction is common in patients with 
TC, which could explain the two of the proposed mechanisms reported at the 
5Takotsubo Syndrome and Nitric Oxide Bioavailability
DOI: http://dx.doi.org/10.5772/intechopen.92235
Author details
Michael Demosthenous1, Konstantinos Triantafyllou2 and Nikolaos Koumallos2*
1 Department of Cardiac Surgery, St. Michael’s Hospital, University of Toronto, 
Toronto, Canada
2 Department of Cardiac Surgery, Hippocration General Hospital, Athens, Greece
*Address all correspondence to: koumallosn@yahoo.gr
beginning of this chapter: propensity for epicardial and/or microvascular coro-
nary artery spasm. Indeed, endothelial dysfunction may be a crucial link between 
myocardial dysfunction seen in TC and stress [38]. Consequently, the reversible LV 
dysfunction seen in TC may be the result of myocardial stunning due to this ephem-
eral myocardial ischemia caused by endothelial dysfunction. This mechanism, 
attenuated by endothelial dysfunction, may also be the cause of high prevalence of 
TC in postmenopausal women due to estrogen level depletion, which is related to 
vasomotor abnormalities [39–41].
Under physiological circumstances, estrogens are beneficial for coronary micro-
circulation. Estrogens have a pivotal role in improving coronary blood flow through 
endothelium-dependent or independent-mechanisms [41]. Reduced estrogen levels 
in menopause positively affect endothelial dysfunction and sympathetic drive [40]. 
Through this effect, postmenopausal estrogen deficiency possibly facilitates the 
occurrence of TC, especially when emotional stress is in the equation.
Endothelial dysfunction is closely associated to the traditional risk factors for 
cardiovascular disease. On the other hand, traditional risk factors for cardiovascular 
disease (smoking, dyslipidemia and hypertension) are present in patients with TC 
in a non-negligible prevalence [42–44]. In addition, there is growing evidence that 
patients with TC also have various comorbidities, including neurological, pulmo-
nary, kidney, and liver disease [42], conditions mostly associated with endothelial 
dysfunction and might therefore constitute a previously unrecognized predisposing 
factor for TC [45].
5. Conclusion
TC is now a well-recognized syndrome with a very complex pathophysiology. 
Increased sympathetic activity and plasma catecholamine levels have a pivotal role 
in the expression of TC. Recent data suggest that endothelial dysfunction and NO 
depletion are crucial predisposing factors for this syndrome and could be a crucial 
link between emotional stress and myocardial dysfunction.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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